Xencor, Inc. $XNCR Stake Trimmed by Deutsche Bank AG

Deutsche Bank AG lowered its stake in Xencor, Inc. (NASDAQ:XNCR) by 9.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,432 shares of the biopharmaceutical company’s stock after selling 5,609 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Xencor worth $558,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its stake in Xencor by 1.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 636,656 shares of the biopharmaceutical company’s stock worth $6,774,000 after purchasing an additional 6,016 shares in the last quarter. Primecap Management Co. CA increased its stake in Xencor by 8.6% in the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock worth $103,857,000 after purchasing an additional 776,580 shares in the last quarter. US Bancorp DE increased its stake in Xencor by 312.0% in the 1st quarter. US Bancorp DE now owns 10,432 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 7,900 shares in the last quarter. XTX Topco Ltd increased its stake in Xencor by 191.7% in the 1st quarter. XTX Topco Ltd now owns 54,209 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 35,627 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Xencor in the 1st quarter worth about $135,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on XNCR shares. Wells Fargo & Company dropped their price target on Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Wedbush dropped their price target on Xencor from $31.00 to $26.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a research note on Thursday, May 8th. Finally, Royal Bank Of Canada lowered their target price on Xencor from $32.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, August 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.71.

Insider Activity at Xencor

In related news, Director Kurt A. Gustafson sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director owned 20,183 shares of the company’s stock, valued at approximately $186,087.26. The trade was a 12.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard J. Ranieri sold 2,993 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares of the company’s stock, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,194 shares of company stock valued at $103,209. 5.23% of the stock is owned by corporate insiders.

Xencor Price Performance

NASDAQ:XNCR opened at $7.90 on Wednesday. The stock has a market cap of $563.43 million, a PE ratio of -3.29 and a beta of 0.89. The stock’s 50-day moving average is $8.31 and its two-hundred day moving average is $10.04. Xencor, Inc. has a fifty-two week low of $6.92 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.37. The business had revenue of $43.61 million during the quarter, compared to analysts’ expectations of $22.59 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The firm’s quarterly revenue was up 82.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.07) EPS. On average, equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.